Overview

A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease

Status:
Withdrawn

Trial end date:
2018-11-04

Target enrollment:

Participant gender:

Summary

This is a study to evaluate the brain metabolic response using Fluorodeoxyglucose Positron Emission Tomography (FDG-PET), safety, tolerability and pharmacokinetics of AGN-242071 in patients with mild to moderate Alzheimer's Disease on a stable dose of 10 mg donepezil with or without memantine standard of care.

Phase:

Phase 1

Details

Lead Sponsor:

Allergan

Treatments:

Donepezil
Memantine